MC3 Cardiopulmonary, a privately owned medical device manufacturer, has launched Crescent jugular dual lumen catheter in the US for extracorporeal membrane oxygenation (ECMO).


Image: MC3 secures FDA clearance for Crescent. Photo: Courtesy of Robina Weermeijer/Unsplash.

MC3 Cardiopulmonary claims that Crescent is the first device cleared by the US Food and Drug Administration (FDA) for ECMO.

The device is placed through the jugular vein and is connected to an ECMO system, which removes carbon dioxide and reinfuses oxygenated blood.

The product’s design is claimed to allow for a flow performance, which can reduce recirculation and enables smooth insertion, visible location and highly durable placement.

MC3 Cardiopulmonary CEO Scott Merz said: “There is an underserved population suffering with lung failure around the world, and the introduction of our Crescent catheter means new options for surgeons and their patients.”

“Until recently, mechanical ventilation with intubation was the last line of defense for millions of patients around the world each year. Due to the advancements in technology available in Crescent, we can now consider cannulating the sickest of these patients instead of intubating them.

“Crescent is the lifeline between the patient and the ECMO system, and we believe vascular access is one of the most important technology segments in healthcare today. Our shared vision with the clinical community is to take standardized ECMO care from possibility to reality.”

The Crescent jugular dual lumen catheter is a single use dual lumen catheter, that offers both venous drainage and reinfusion of blood via the jugular vein and it is useful for patients with acute respiratory failure who require Veno-Venous Extracorporeal Membrane Oxygenation where other available treatment options have failed and continued clinical deterioration is expected or when there is an imminent risk of death.

MC3 Cardiopulmonary was established in 1991, with a specific aim of commercializing intellectual property related to artificial heart and lung technologies from the University of Michigan.

The company aims to provide the global community by developing life restoring medical devices that address acute and chronic unmet cardiopulmonary clinical needs.

Crescent is the company’s first FDA cleared device labeled with a long-term Extracorporeal Membrane Oxygenation (ECMO) indication in the United States. Global sales channel of the company is managed by Medtronic.